Aquestive Therapeutics Inc (AQST)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Aquestive Therapeutics Inc Stock (AQST) Company Profile

Aquestive Therapeutics Inc

Healthcare (1104)

908-941-1900

30 TECHNOLOGY DRIVE, WARREN, NJ

Nächster Verdiensttermin

Neueste SEC-Einreichungen

AQST's Discussions on Twitter

Compare AQST vs TAK, HLN, TEVA, ZTS, UTHR

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
AQST Aquestive Therapeutics Inc	4.71	590.87M	50.27M	-68.91M	-44.32M	-0.603
TAK Takeda Pharmaceutical Co Adr	15.63	49.39B	29.91B	1.30B	3.49B	0.4056
HLN Haleon Plc Adr	8.96	39.55B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	31.48	36.66B	17.53B	1.58B	444.18M	1.3457
ZTS Zoetis Inc	78.71	33.00B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	536.59	22.78B	3.17B	1.29B	1.01B	27.09

Aquestive Therapeutics Inc Stock (AQST) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-04-24	Fortgesetzt	Oppenheimer	Outperform
2025-06-02	Fortgesetzt	Oppenheimer	Outperform
2024-12-17	Eingeleitet	Cantor Fitzgerald	Overweight
2024-05-10	Eingeleitet	Leerink Partners	Outperform
2024-04-11	Eingeleitet	Piper Sandler	Overweight
2024-03-28	Eingeleitet	Raymond James	Outperform
2021-04-07	Fortgesetzt	RBC Capital Mkts	Outperform
2019-04-22	Eingeleitet	H.C. Wainwright	Buy
2019-01-03	Eingeleitet	Lake Street	Buy
2018-08-20	Eingeleitet	JMP Securities	Mkt Outperform
2018-08-20	Eingeleitet	RBC Capital Mkts	Outperform

Alle ansehen

Aquestive Therapeutics Inc Aktie (AQST) Neueste Nachrichten

Finanzdaten der Aquestive Therapeutics Inc-Aktie (AQST)

Aquestive Therapeutics Inc (AQST)

Aquestive Therapeutics Inc Stock (AQST) Company Profile

Compare AQST vs TAK, HLN, TEVA, ZTS, UTHR

Aquestive Therapeutics Inc Stock (AQST) Upgrades & Downgrades

Aquestive Therapeutics Inc Aktie (AQST) Neueste Nachrichten

Bronstein, Gewirtz & Grossman, LLC Is Investigating Aquestive Therapeutics, Inc. (AQST) And Encourages Shareholders to Connect - ACCESS Newswire

Aquestive Therapeutics (NYSE:AQST): What Insider Activity Reveals About Corporate Confidence - Kalkine Media

Have Aquestive Therapeutics Insiders Been Selling Stock? - simplywall.st

Aquestive Therapeutics Inc (AQST) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Aquestive Therapeutics Inc (AQST) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Aquestive Therapeutics Inc (AQST) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Aquestive Therapeutics Inc (AQST) Institutional Confidence - TradingKey

Aquestive Therapeutics Inc (AQST) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Aquestive Therapeutics Inc (AQST) Valuation: PE, PB & Fair Value Analysis - TradingKey

Aquestive Therapeutics Inc (AQST) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Aquestive Therapeutics Inc (AQST) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Aquestive Therapeutics CEO sells $104,010 in company stock By Investing.com - Investing.com Canada

Aquestive Therapeutics CEO sells $104,010 in company stock - Investing.com UK

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aquestive Therapeutics, Inc. (AQST) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review

2026-06-14 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aquestive Therapeutics, Inc. (AQST) and Encourages Shareholders to Learn More About the Investigation | NDAQ:AQST | Press Release - Stockhouse

Aquestive Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Krop Julie - Moomoo

Aquestive (AQST) awards Abigail Jenkins 50,500 stock options at $3.99 - Stock Titan

Aquestive Therapeutics (AQST) director receives 50,500 stock options grant - Stock Titan

Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeutics, Inc. (AQST) Stockholders to Inquire about Securities Investigation - ACCESS Newswire

AQST: FDA progress, global expansion, and all proposals passed with strong shareholder support - TradingView

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aquestive Therapeutics, Inc. (AQST) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire

Aquestive Therapeutics, Inc. (AQST) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

Aquestive Therapeutics, Inc. (AQST) Investigation: Bronstein, Gew - The National Law Review

AQUESTIVE THERAPEUTICS INC (AQST) Stock Chart - ChartMill

Aquestive Therapeutics: Rating Downgrade Despite Probability Of Anaphylm Approval - Seeking Alpha

Bronstein, Gewirtz & Grossman, LLC Is Investigating Aquestive Therapeutics, Inc. (AQST) And Encourages Investors to Connect - ACCESS Newswire

2026-06-04 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Aquestive Therapeutics, Inc. (AQST) And Encourages Investors to Connect | NDAQ:AQST | Press Release - Stockhouse

Aquestive Therapeutics Q1 earnings call highlights - MSN

AQST: Aquestive TherapeuticsInteractive Chart - Zacks Investment Research

Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeut - The National Law Review

2026-06-02 | Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeutics, Inc. (AQST) Stockholders to Inquire about Securities Investigation | NDAQ:AQST | Press Release - Stockhouse

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aquestive Therapeutics, Inc. (AQST) And Encourages Stockholders to Reach Out - ACCESS Newswire

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review

Bronstein, Gewirtz & Grossman, LLC Is Investigating Aquestive Therapeutics, Inc. (AQST) And Encourages Stockholders to Connect - ACCESS Newswire

Aquestive Therapeutics, Inc. (AQST) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

Aquestive Therapeutics Charts Cautious, Liquid Path Forward - TipRanks

Aquestive Therapeutics CEO sells $35,413 in company stock By Investing.com - Investing.com South Africa

Aquestive Therapeutics CEO sells $35,413 in company stock - Investing.com UK

PRN_FinancialWrapper - FinancialContent

Aquestive secures $150 million debt facility with Oaktree By Investing.com - Investing.com Nigeria

Aquestive targets Q3 FDA resubmission for Anaphylm and projects >$150M cash at launch - MSN

A Quick Look at Today's Ratings for Aquestive Therapeutics(AQST.US), With a Forecast Between $6 to $9 - Moomoo

Analysts Offer Insights on Healthcare Companies: Aquestive Therapeutics (AQST) and Ardent Health Partners, Inc. (ARDT) - The Globe and Mail

Analysts Are Bullish on These Healthcare Stocks: Aquestive Therapeutics (AQST), Monopar Therapeutics Inc (MNPR) - The Globe and Mail

All News about Aquestive Therapeutics, Inc.Common Stock - The Chronicle-Journal

Lake Street Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $6 - Moomoo

Aquestive Says It’s on Track to Launch Anaphylm Studies for FDA - Allergic Living

Analysts Have Made A Financial Statement On Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) First-Quarter Report - Moomoo

The Aquestive Therapeutics, Inc. (NASDAQ:AQST) First-Quarter Results Are Out And Analysts Have Published New Forecasts - Yahoo Finance

Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q1 2026 Earnings Call Transcript - Insider Monkey

Finanzdaten der Aquestive Therapeutics Inc-Aktie (AQST)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie AQST